NCT07074665View on ClinicalTrials.gov

Dose Finding Trial of R21/Matrix-M in School Children

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

December 31, 2026

Conditions
Malaria (Plasmodium Falciparum)
Interventions
BIOLOGICAL

5µg R21/50µg Matrix-M

R21/Matrix-M is a vaccine against P. falciparum malaria, which has WHO prequalification and policy recommendation in children over 5 months old in malaria endemic areas. The standard paediatric dose is 5µg R21/50µg Matrix-M.

BIOLOGICAL

10µg R21/50µg Matrix-M

R21/Matrix-M is a vaccine against P. falciparum malaria, which has WHO prequalification and policy recommendation in children over 5 months old in malaria endemic areas. 10µg R21/50µg Matrix-M is the standard adult dose.

Trial Locations (1)

PO Box 11 BP 218 Ouaga CMS 11

Unité de Recherche Clinique de Nanoro (URCN), Nanoro

All Listed Sponsors
collaborator

Institut de Recherche en Sciences de la Sante, Burkina Faso

OTHER_GOV

lead

University of Oxford

OTHER